DIA Biosimilars 2013

Nile Therapeutics

Capricor to merge with Nile Therapeutics

Monday, July 8, 2013 12:30 PM

Capricor, a privately held biotechnology company developing cardiac stem cell (CDC) therapeutics to repair damaged heart muscle, and biopharmaceutical company Nile Therapeutics have entered into a merger agreement under which Capricor will become a wholly owned subsidiary of Nile Therapeutics in an all-stock transaction.

More... »

Cenduit: Now with Patient Reminders

Nile Therapeutics promotes Horton to president, CEO, director

Thursday, August 9, 2012 03:06 PM

Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure, has promoted Darlene Horton, M.D. to president, CEO and director of the company.

More... »

CRF Health – eCOA Forum

Nile Therapeutics appoints Darlene Horton as CMO

Friday, June 22, 2012 10:19 AM

Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure patients, has appointed Darlene Horton, M.D. as its chief medical officer.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs